Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA/
      2. Our innovation /
      3. Focus areas/
      4. Immunology

      Immunology

      We understand how distressing and debilitating immune-mediated inflammatory diseases (IMIDs) can be, which is why we strive to provide treatments that give you or your loved ones relief from the daily discomfort and stress that these conditions can pose. Rest assured, we are committed to building on our breakthroughs that have already changed the lives of millions of people around the world.
      Smiling female looking up while standing outdoors
      Our commitment to patients
      Johnson & Johnson is committed to help ease the challenges that people living with immune-mediated inflammatory diseases have to endure for the rest of their lives.

      Our goal is to improve the diagnosis of immune-mediated inflammatory diseases, improve patients’ access to the best possible treatments and continue to provide new and better medicines.
      JNJ_Microscopic_Illustration_Bacteria_Colorway02
      We never underestimate the human impact of immune-mediated inflammatory diseases
      People living with immune-mediated inflammatory diseases can be affected for the rest of their lives, yet the impact of these conditions is dramatically underestimated. As some of these diseases are not readily recognised, people can suffer silently before eventually receiving treatment.
      Immune-mediated inflammatory diseases are the result of a relentless, internal, immunological ‘storm’, which can cause pain and discomfort that many people live with every day[1], [2], [3]. People may further experience stigma, isolation, decreased productivity and psychological issues[2], [4], [5], [6], [7]. And it’s not just them, their families and loved ones can be affected too[4] .

      Our mission is clear: we won’t rest until we achieve a world free from immune-mediated inflammatory diseases.
      Leveraging shared pathology across diseases to broaden therapeutic opportunities

      Significant unmet treatment need exists for a range of serious autoantibody mediated autoimmune diseases.[8] Autoantibody diseases are caused by pathogenic antibodies made by one’s own body that attack organs and tissues, and, in pregnant individuals, maternal alloantibodies can attack the organs and tissues of the fetus. [9][10][11][12][13][14][15][16][17]

      Autoantibody diseases are associated with significant morbidity and mortality worldwide. They include a large and varied group of more than 80 chronic autoimmune and acute alloimmune conditions, that span rare and prevalent diseases.[8][18][19][20][21] European studies indicate that between 7.6 and 10.2% of the continental population are affected by severe autoantibody diseases, with many patients without safe, effective treatments for their conditions. [22][23][24]

      Johnson & Johnson is committed to deepening our research in allo- and autoantibody diseases, such as myasthenia gravis, haemolytic disease of the foetus and newborn and chronic inflammatory demyelinating polyneuropathy, to help address the significant unmet need for therapies and treatments for patients. We aim to revolutionise care for patients with a novel approach that reduces pathogenic antibodies while safely maintaining immune function, furthering our goal to redefine treatments for immune diseases.

      Our treatment areas
      We are proud to have one of the strongest treatment portfolios for some of the most common immune-mediated inflammatory diseases.
      Dermatology
      Our focus in Dermatology is inflammatory conditions of the skin.
      June 17, 2024
      Rheumatology
      Our focus in Rheumatology is currently inflammatory disorders of the joints and skin.
      June 17, 2024
      Gastroenterology
      Our focus in Gastroenterology is inflammatory bowel disease.
      June 17, 2024
      Immunology facts
      • Living with an immune-mediated inflammatory disease has a similar impact on psychological and physical functioning to cancer, heart disease and hypertension.[9],[10]
      • They are debilitating and chronic diseases. Pain, fatigue and inability to perform everyday tasks are the most apparent symptoms.[11],[12], [13], [14], [15], [16], [17]
      • Many people also suffer from severe additional conditions as a result, such as depression.[13],[14], [18],[19]
      • Nearly 1 in 10 people in Europe are living with an immune-mediated inflammatory disease.[8]
      banner-male_nurse_consulting_with_patients_stock_gettyimages-1309072306.png
      Johnson & Johnson is pioneering breakthroughs that change lives
      We’ve always been innovative in our science, finding new and more effective ways to transform the course of immune-mediated inflammatory diseases and calm the inner battle waging within patients’ bodies.

      Our breakthroughs have changed the lives of millions of people around the world living with some of the most common immune-mediated inflammatory diseases.
      JJIM_Photo_RetinalMicroscopy_01_3016.jpg
      We will continue our search for newer and better medicines
      We’ve continued to advance our knowledge of the inflammatory process. We’ll carry on working on better therapies to try to stop and even cure immune-mediated inflammatory diseases, where the impact on patients is high and/or where there remains a need for better treatments.
      JJ_Photo_Close up gloved hand holding centrifuge tube_IM_3Star.jpg
      Working together to achieve a world where immune-mediated inflammatory diseases are a thing of the past
      Our commitment to immune-mediated inflammatory diseases goes beyond our medicines. We support patients through collaborations with patient advocacy organisations.[22]

      We invest heavily in continuous medical education of doctors and care providers, uniting different therapeutic areas to share expertise and best practices.
      We also bring together the brightest minds, including doctors, nurses, patients and patient groups, scientists and policy makers to turn scientific discoveries into treatment breakthroughs, and to ensure that people can benefit from the best treatments when they need them.
      Learn more
      Even though we have made great progress in the last decade for the treatment of immune-mediated inflammatory diseases, our work aims to raise the bar to make periods of disease remission more durable and allow patients with these debilitating diseases to lead normal lives.”
      Ludovic de Beaucoudrey, PhD
      JANSSEN THERAPEUTIC AREA LEAD, IMMUNOLOGY, EUROPE, MIDDLE EAST & AFRICA
      My IBD Journey
      Looking for practical tips on living with inflammatory bowel disease (IBD)? Head to the My IBD Journey page, where you will find a series of short animations providing helpful advice about living well with IBD. These animations have been developed in association with the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA ).
      Beyond Expectations
      If you want to learn more about psoriasis or psoriatic arthritis, check out Beyond Expectations, our online patient portal for people living with psoriatic disease or who are interested in learning more about the disease and treatment options..

      References

      [1] Lofvendahl, S., et al. Incremental costs for psoriasis and psoriatic arthritis in a population-based cohort in southern Sweden: is it all psoriasis-attributable morbidity? Journal of Rheumatology, 2016;43(3):640-647

      [2] Lonffors, S., et al. IBD and health-related quality of life - discovering the true impact. Journal of Crohn’s and Colitis, 2014;8:1281-1286

      [3] Najafi, S., et al. The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. Clin Rheumatol, 2020;39:3223–3235

      [4] Eghlileb, A.M., et al. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol, 2007;156(6):1245-50

      [5] Dibley, L., et al. The experience of stigma in inflammatory bowel disease: An interpretive (hermeneutic) phenomenological study. J Adv Nurs, 2018;74:838-851

      [6] Ograczyk, A., et al. Itch, disease coping strategies and quality of life in psoriasis patients. Postepy Dermatologi Alergologii, 2014;5:299-304

      [7] Narayanan, S., et al. 2014. Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study. Psoriasis (Auckl), 2014;5:1-7

      [8] Ludwig RJ, et al. Mechanisms of Autoantibody-Induced Pathology. Front Immunol. 2017;8:603. Doi:10.3389/fimmu.2017.00603.

      [9] Momenta Pharmaceuticals. Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN. GlobeNewswire News Room. Published July 28, 2020. Accessed June 2024. https://www.globenewswire.com/news-release/2020/07/28/2068533/0/en/Momenta-Pharmaceuticals-Announces-FDA-Rare-Pediatric-Disease-Designation-for-Nipocalimab-in-HDFN.html.

      [10] Osanan GC, Silveira Reis ZN, Apocalypse IG, et al. Predictive factors of perinatal mortality in transfused fetuses due to maternal alloimmunization: what really matters? J Matern Fetal Neonatal Med. 2012;25(8):1333-1337. Doi:10.3109/14767058.2011.633668 https://pubmed.ncbi.nlm.nih.gov/22046976/.

      [11] Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primer. 2019;5(1):30. doi:10.1038/s41572-019-0079-y https://pubmed.ncbi.nlm.nih.gov/31048702/.

      [12] Bacci ED, Coyne KS, Poon JL, Harris L, Boscoe AN. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019;19(1):335. Doi:10.1186/s12883-019-1573-2 https://pubmed.ncbi.nlm.nih.gov/31864345/.

      [13] Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. Front Neurol. 2020;11:538. doi:10.3389/fneur.2020.00538 https://pubmed.ncbi.nlm.nih.gov/32714266.

      [14] Schett G, Teitelbaum SL. Osteoclasts and Arthritis. J Bone Miner Res. 2009;24(7):1142-1146. doi:10.1359/jbmr.090533 https://pubmed.ncbi.nlm.nih.gov/19557892/.

      [15] Kocijan R, Harre U, Schett G. ACPA and bone loss in rheumatoid arthritis. Curr Rheumatol Rep. 2013;15(10):366. doi:10.1007/s11926-013-0366-7 https://pubmed.ncbi.nlm.nih.gov/23955066/.

      [16] Sieghart D, Platzer A, Studenic P, et al. Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis. Front Immunol. 2018;9:876. doi:10.3389/fimmu.2018.00876 https://pubmed.ncbi.nlm.nih.gov/29740454/.

      [17] Taylor PC, Schett G, Fowzia I, et al. Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2a IRIS-RA Study. Data presentation at American College of Rheumatology Convergence 2023, November 10-15.

      [18] Eggert M, Zettl UK, Neeck G. Autoantibodies in autoimmune diseases. Curr Pharm Des. 2010;16(14):1634-1643. doi:10.2174/138161210791164144 https://pubmed.ncbi.nlm.nih.gov/20196735.

      [19] Quick MB Jen Christiansen,Miriam. The Terrible Toll of 76 Autoimmune Diseases. Scientific American. doi:10.1038/scientificamerican0921-31 https://www.scientificamerican.com/article/the-terrible-toll-of-76-autoimmune-diseases.

      [20] Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev. 2012;11(10):754-765. doi:10.1016/j.autrev.2012.02.001.

      [21] Autoimmune Registry, Inc, 2016-2020 https://www.autoimmuneregistry.org/autoimmune-diseases

      [22] Conrad N, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 2023 Jun 3;401(10391):1878-1890. doi: 10.1016/S0140-6736(23)00457-9

      [23] Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009 Nov-Dec;33(3-4):197-207. doi: 10.1016/j.jaut.2009.09.008. Epub 2009 Oct 9. PMID: 19819109; PMCID: PMC2783422.

      [24] Wofsy D. Strategies for treating autoimmune disease with monoclonal antibodies. West J Med. 1985 Dec;143(6):804-9. PMID: 3911593; PMCID: PMC1306490.

      [25] Cooper, G.S., et al. Recent Insights in the Epidemiology of Autoimmune Diseases: Improved Prevalence Estimates and Understanding of Clustering of Diseases. J Autoimmun. 2009;33(3-4):197-207

      [26] Mease P. Assessing impact of Psoriatic Arthritis on Patient Function and Quality of Life: Lessons Learned from Other Rheumatologic Conditions. Semin Arthritis Rheum, 2009;38(4):320-335

      [27] Walker, J., Littlejohn, G. Measuring quality of life in Rheumatic conditions. Clin Rheumatol, 2017; 26,p:671-673

      [28] Lupus Foundation of America. Lupus facts and statistics. 2016. Available at: https://www.lupus.org/resources/lupus-facts-and-statistics. Accessed: October 2022

      [29] Scotti, L., et al. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arth Rheum. 2018;48:28-34

      [30] Bacconier, L., et al. Psychological distress over time in early rheumatoid arthritis: results from a longitudinal study in an early arthritis cohort. Rheumatology (Oxford) 2015;54(3):520-7

      [30] Pompili, M., et al. Suicide risk and psychiatric comorbidity in patients with psoriasis. J Int Med Res. 2016;44(IS):61-66

      [31] Amador-Patarroyo. M.J., et al. How does age at onset influence the outcome of autoimmune diseases? Autoimmune Dis, 2012;251730

      [32] Habibi, F., et al. Quality of life in inflammatory bowel disease patients: A cross-sectional study. J Res Med Sci, 2017;22:104

      [33] Becker, H.M., et al. Living with inflammatory bowel disease: A Crohn’s and Colitis Canada survey. Can J Gastroenterol Hepatol, 2015;29(2):77-84

      [34] Shah, K., et al. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open, 2017;3(2):3

      [35] Bernstein, C.N., et al. Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(2):360-368

      [36] Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-116

      [37] EFCCA. My IBD Journey – animation series. 2019. Available at: https://efcca.org/projects/my-ibd-journey-animation-series. Accessed: October 2022

      CP-507298
      June 2025